Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers
Purpose We investigated serum uric acid changes in relation to the achieved clinic and ambulatory blood pressure after 8 weeks of antihypertensive therapy with two dihydropyridine calcium channel blockers. Materials and methods The study participants were patients with clinic and ambulatory hyperten...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-11-01
|
| Series: | Blood Pressure |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/08037051.2021.1996220 |
| _version_ | 1797676878578843648 |
|---|---|
| author | Di Zhang Qi-Fang Huang Chang-Sheng Sheng Yan Li Ji-Guang Wang |
| author_facet | Di Zhang Qi-Fang Huang Chang-Sheng Sheng Yan Li Ji-Guang Wang |
| author_sort | Di Zhang |
| collection | DOAJ |
| description | Purpose We investigated serum uric acid changes in relation to the achieved clinic and ambulatory blood pressure after 8 weeks of antihypertensive therapy with two dihydropyridine calcium channel blockers. Materials and methods The study participants were patients with clinic and ambulatory hypertension, enrolled in a randomised controlled trial that compared amlodipine (5–10 mg, n = 215) and nifedipine gastrointestinal therapeutic system (GITS, 30–60 mg, n = 203). Hyperuricaemia was defined as a serum uric acid concentration of ≥420 µmol/L in men and ≥360 µmol/L in women. Analysis of covariance and multiple regression analyses were performed to study the associations between serum uric acid changes and the achieved clinic and ambulatory blood pressure during follow-up. Results At baseline, 67 (16.0%) of the 418 patients had hyperuricaemia. Antihypertensive treatment reduced clinic and 24-h daytime and night-time systolic/diastolic blood pressure by a mean (±standard error [SE]) change of −17.4 ± 0.6/−8.6 ± 0.4 mm Hg and −13.7 ± 0.5/−8.3 ± 0.3 mm Hg, −13.8 ± 0.6/−8.4 ± 0.4 mm Hg, and −12.7 ± 0.7/−8.0 ± 0.4 mm Hg, respectively. Antihypertensive treatment reduced serum uric acid by a mean (±SE) change of −9.3 ± 2.8 μmol/L. The serum uric acid changes differed according to the achieved clinic and ambulatory blood pressure, and were statistically significant (mean ± SE −20.6 ± 6.6 to −10.7 ± 2.9 μmol/L, p ≤ 0.04) at the systolic/diastolic ranges of 130–139/≥90 mm Hg in clinic pressure, and <130/75–84 mm Hg, <145/80–84 mm Hg and <120/65–69 mm Hg in 24-h, daytime and night-time ambulatory pressure. Conclusion Our study showed that antihypertensive therapy with a dihydropyridine calcium channel blocker was associated with reduced serum uric acid, especially when 24-h ambulatory systolic blood pressure was controlled. |
| first_indexed | 2024-03-11T22:35:48Z |
| format | Article |
| id | doaj.art-54ffd13519a74707b83af236ed10e2ea |
| institution | Directory Open Access Journal |
| issn | 0803-7051 1651-1999 |
| language | English |
| last_indexed | 2024-03-11T22:35:48Z |
| publishDate | 2021-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Blood Pressure |
| spelling | doaj.art-54ffd13519a74707b83af236ed10e2ea2023-09-22T13:54:18ZengTaylor & Francis GroupBlood Pressure0803-70511651-19992021-11-0130639540210.1080/08037051.2021.19962201996220Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockersDi Zhang0Qi-Fang Huang1Chang-Sheng Sheng2Yan Li3Ji-Guang Wang4Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of MedicineCentre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of MedicineCentre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of MedicineCentre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of MedicineCentre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of MedicinePurpose We investigated serum uric acid changes in relation to the achieved clinic and ambulatory blood pressure after 8 weeks of antihypertensive therapy with two dihydropyridine calcium channel blockers. Materials and methods The study participants were patients with clinic and ambulatory hypertension, enrolled in a randomised controlled trial that compared amlodipine (5–10 mg, n = 215) and nifedipine gastrointestinal therapeutic system (GITS, 30–60 mg, n = 203). Hyperuricaemia was defined as a serum uric acid concentration of ≥420 µmol/L in men and ≥360 µmol/L in women. Analysis of covariance and multiple regression analyses were performed to study the associations between serum uric acid changes and the achieved clinic and ambulatory blood pressure during follow-up. Results At baseline, 67 (16.0%) of the 418 patients had hyperuricaemia. Antihypertensive treatment reduced clinic and 24-h daytime and night-time systolic/diastolic blood pressure by a mean (±standard error [SE]) change of −17.4 ± 0.6/−8.6 ± 0.4 mm Hg and −13.7 ± 0.5/−8.3 ± 0.3 mm Hg, −13.8 ± 0.6/−8.4 ± 0.4 mm Hg, and −12.7 ± 0.7/−8.0 ± 0.4 mm Hg, respectively. Antihypertensive treatment reduced serum uric acid by a mean (±SE) change of −9.3 ± 2.8 μmol/L. The serum uric acid changes differed according to the achieved clinic and ambulatory blood pressure, and were statistically significant (mean ± SE −20.6 ± 6.6 to −10.7 ± 2.9 μmol/L, p ≤ 0.04) at the systolic/diastolic ranges of 130–139/≥90 mm Hg in clinic pressure, and <130/75–84 mm Hg, <145/80–84 mm Hg and <120/65–69 mm Hg in 24-h, daytime and night-time ambulatory pressure. Conclusion Our study showed that antihypertensive therapy with a dihydropyridine calcium channel blocker was associated with reduced serum uric acid, especially when 24-h ambulatory systolic blood pressure was controlled.http://dx.doi.org/10.1080/08037051.2021.1996220serum uric acidantihypertensive therapyclinic blood pressureambulatory blood pressuredihydropyridine calcium channel blocker |
| spellingShingle | Di Zhang Qi-Fang Huang Chang-Sheng Sheng Yan Li Ji-Guang Wang Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers Blood Pressure serum uric acid antihypertensive therapy clinic blood pressure ambulatory blood pressure dihydropyridine calcium channel blocker |
| title | Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers |
| title_full | Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers |
| title_fullStr | Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers |
| title_full_unstemmed | Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers |
| title_short | Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers |
| title_sort | serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers |
| topic | serum uric acid antihypertensive therapy clinic blood pressure ambulatory blood pressure dihydropyridine calcium channel blocker |
| url | http://dx.doi.org/10.1080/08037051.2021.1996220 |
| work_keys_str_mv | AT dizhang serumuricacidchangeinrelationtoantihypertensivetherapywiththedihydropyridinecalciumchannelblockers AT qifanghuang serumuricacidchangeinrelationtoantihypertensivetherapywiththedihydropyridinecalciumchannelblockers AT changshengsheng serumuricacidchangeinrelationtoantihypertensivetherapywiththedihydropyridinecalciumchannelblockers AT yanli serumuricacidchangeinrelationtoantihypertensivetherapywiththedihydropyridinecalciumchannelblockers AT jiguangwang serumuricacidchangeinrelationtoantihypertensivetherapywiththedihydropyridinecalciumchannelblockers |